Bruker Corporation
NASDAQ:BRKRMedical - Devices
-$1.07 today
- Market cap
- $9.66B
- Beta
- 1.30
- P/E (TTM)
- -718.1
- EPS (TTM)
- -$0.08
- Dividend yield
- 0.37%
Volume 1.73M
Average 2.41M
BRKR Common Stock Repurchased
Cash spent buying back the company's own shares.
Bruker CorporationNASDAQ: BRKR
Common Stock Repurchased · Q2 FY2026 · quarter ended Jun 2026
Common stock repurchased outflow grows to $0
Q2 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0. Over 3 fiscal years it compounded at -66.4% a year.
Context
- Common stock repurchased amounted to 0.3% of revenue in FY2025, up 0.3 pp from a year earlier.
- Common stock repurchased increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Repurchased history
USD · from the cash flow
- Latest · FY2025
- (10M) USD
- Year-over-year change
- —
| Period | Period end | Common Stock Repurchased | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10M) | — |
| FY2024 | 2024-12-31 | 0 | +100.0% |
| FY2023 | 2023-12-31 | (152.3M) | +42.1% |
| FY2022 | 2022-12-31 | (263.1M) | -71.6% |
| FY2021 | 2021-12-31 | (153.3M) | — |
Common Stock Repurchased vs competitors
How BRKR compares with its peers on the latest reported figures
- BRKR's LTM Jun 2026 common stock repurchased of $0 is the 10th largest of the 11 companies compared; the peer median is $427.9M.
- Its year-over-year change of +100.0% is the 2nd highest of 10, against a peer median of -39.5%.
- Common stock repurchased amounts to 0.0% of revenue for BRKR, versus a peer median of 5.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $7B | +600.0% | +0.0% | 14.8% | |
| LTM Sep 2026 | $919M | -76.3% | — | 3.6% | |
| LTM Jun 2026 | $775M | -10.1% | -10.1% | 18.7% | |
| LTM Jun 2026 | $508.79M | +71.0% | +129.7% | 24.2% | |
| LTM Jul 2026 | $475.8M | -39.5% | +116.7% | 16.3% | |
| LTM Jul 2026 | $380M | -43.7% | -28.0% | 5.2% | |
| LTM Jun 2026 | $132.7M | -61.0% | +11.1% | 5.1% | |
| LTM Sep 2026 | $41.65M | -84.9% | +28.7% | 3.4% | |
| LTM Jul 2026 | $14.36M | -1.1% | -71.4% | 0.3% | |
| LTM Jun 2026 | $0 | +100.0% | -66.4% | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BRKR) | $427.9M | -39.5% | +5.5% | 5.1% | |
Competitors are the stored peer set for BRKR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 280.6M | 298.5M | 427.2M | 113.8M | (8.3M) |
| Depreciation & Amortization | 89.1M | 88.7M | 114.9M | 183.8M | 220.3M |
| Deferred Income Tax | (5.8M) | (14.8M) | (24.4M) | (63.8M) | (104.5M) |
| Stock-Based Compensation | 17.2M | 27.7M | 24M | 25.3M | 20.2M |
| Change in Working Capital | (125.2M) | (144.1M) | (87.8M) | (78.2M) | (144.8M) |
| Accounts Receivables | (95.3M) | (67.9M) | (900K) | (40.6M) | 54.2M |
| Inventory | (67M) | (137.9M) | (125M) | (69.8M) | 12.1M |
| Accounts Payables | 61.8M | 33.3M | 23.1M | 20.8M | (37.5M) |
| Other Working Capital | (24.7M) | 28.4M | 15M | 11.4M | (173.6M) |
| Other Non-Cash Items | 26.5M | 18.4M | (103.8M) | 70.4M | 151.2M |
| Operating Cash Flow | 282.4M | 274.4M | 350.1M | 251.3M | 134.1M |
| Capital Expenditures | (92M) | (129.2M) | (106.9M) | (115.3M) | (120.2M) |
| Acquisitions (Net) | (65M) | (182.3M) | (226.6M) | (1.6B) | (73.9M) |
| Purchases of Investments | (148.5M) | (60.2M) | (24.8M) | (48.3M) | (7.2M) |
| Sales of Investments | 108.2M | 106.2M | 21.2M | 4.8M | 0 |
| Other Investing Activities | 4.9M | 13.9M | 11.1M | 1.1M | (24.6M) |
| Investing Cash Flow | (192.4M) | (251.6M) | (326M) | (1.76B) | (196.5M) |
| Debt Repayment | 489.7M | (110.7M) | (21.5M) | 875.9M | (491.3M) |
| Common Stock Issued | 7M | 2.8M | 9.5M | 403M | 669.7M |
| Common Stock Repurchased | (153.3M) | (263.1M) | (152.3M) | 0 | (10M) |
| Dividends Paid | (24.2M) | (29.8M) | (29.4M) | (30.2M) | (22.8M) |
| Other Financing Activities | (500K) | (14.5M) | 300K | (18.9M) | (10.5M) |
| Financing Cash Flow | 318.7M | (415.3M) | (193.4M) | 1.23B | 135.1M |
| Effect of Forex Changes | (22.5M) | (30.5M) | 12.2M | (28.7M) | 43.7M |
| Net Change in Cash | 386.2M | (423M) | (157.1M) | (304.9M) | 116.4M |
| Free Cash Flow | 190.4M | 145.2M | 243.2M | 136M | 13.9M |
Bruker Corporation
NASDAQ:BRKR
Intrinsic Alpha fair value
Locked
Current Price
$63.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.